Celcuity (NASDAQ:CELC) Price Target Raised to $125.00

Key Points

• Stifel Nicolaus raised its price target on Celcuity from $115 to $125 and kept a "buy" rating, joining other firms (Jefferies, Wells Fargo, Needham) that have recently lifted targets; the consensus rating is a Moderate Buy with an average price target of $109.88.
• Shares traded at about $113.35 mid-day (market cap ~$5.24B) and the company remains loss-making, but Q4 EPS beat estimates (‑$0.73 vs. ‑$1.06) and Celcuity highlights a potential ~$2.5B peak revenue opportunity for gedatolisib as its breast cancer program nears regulatory milestones.
• Insider activity: Director David Dalvey sold 20,000 shares at $120.03 (an 18.18% reduction in his holdings); insiders own 15.77% of the stock while institutional investors hold 63.33%.

Celcuity (NASDAQ:CELC - Get Free Report) had its price objective lifted by research analysts at Stifel Nicolaus from $115.00 to $125.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Stifel Nicolaus' target price suggests a potential upside of 10.28% from the stock's current price.

A number of other research firms also recently issued reports on CELC. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Celcuity in a research note on Wednesday, January 21st. Jefferies Financial Group increased their price objective on shares of Celcuity from $108.00 to $134.00 and gave the company a "buy" rating in a research report on Tuesday, December 2nd. Wells Fargo & Company assumed coverage on shares of Celcuity in a research note on Friday, December 12th. They issued an "overweight" rating and a $126.00 price objective for the company. Wolfe Research restated an "outperform" rating and set a $110.00 target price on shares of Celcuity in a research report on Thursday, March 12th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $122.00 price target on shares of Celcuity in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Celcuity currently has a consensus rating of "Moderate Buy" and a consensus price target of $109.88.

Celcuity Price Performance

Shares of CELC traded up $3.13 during mid-day trading on Thursday, hitting $113.35. 189,359 shares of the stock were exchanged, compared to its average volume of 708,319. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. The company has a market cap of $5.24 billion, a PE ratio of -30.65 and a beta of 0.38. Celcuity has a 52-week low of $7.57 and a 52-week high of $120.32. The firm has a 50-day moving average of $109.32 and a two-hundred day moving average of $90.27.

Insider Buying and Selling

In other news, Director David Dalvey sold 20,000 shares of the stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total value of $2,400,600.00. Following the sale, the director owned 90,000 shares of the company's stock, valued at approximately $10,802,700. This represents a 18.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 15.77% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CELC. Hsbc Holdings PLC bought a new stake in Celcuity during the 4th quarter valued at about $1,058,000. Seven Fleet Capital Management LP purchased a new position in shares of Celcuity during the fourth quarter worth approximately $783,000. Invesco Ltd. raised its stake in shares of Celcuity by 4.9% during the fourth quarter. Invesco Ltd. now owns 147,938 shares of the company's stock valued at $14,755,000 after acquiring an additional 6,928 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Celcuity during the fourth quarter valued at approximately $376,000. Finally, KVP Capital Advisors LP purchased a new stake in shares of Celcuity in the fourth quarter valued at approximately $399,000. Hedge funds and other institutional investors own 63.33% of the company's stock.

Celcuity News Summary

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Needham reaffirmed a "buy" and raised its price target to $122, signaling incremental analyst optimism and indicating upside versus the current market level. Needham Price Target Raise
• Positive Sentiment: Q4 results beat estimates on the bottom line: EPS of ($0.73) beat consensus ($1.06) — a clear near-term financial beat that reduces near-term downside risk vs. expectations. Earnings Release / Transcript
• Positive Sentiment: Company guidance/updates and analyst commentary outline a potential ~ $2.5B annual peak revenue opportunity for gedatolisib if pivotal milestones and commercial launch succeed — a large-market thesis that supports long-term upside. Gedatolisib Peak Revenue Article
• Positive Sentiment: Coverage noting the breast cancer program is nearing regulatory milestones/approval has increased investor excitement about an upcoming value-inflection event. Drug Approval Coverage
• Neutral Sentiment: Earnings call/transcript highlights underscore that the company is still operating at a loss while advancing the program — typical for a clinical‑stage biotech and a reminder of execution risk even as the pipeline shows promise. Earnings Call Transcript
• Neutral Sentiment: Short-interest data reported in several sources appears anomalous (shows zero shares), so recent headlines about "large increases" are likely unreliable; no clear short-squeeze signal from the reported figures.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.